Topics

Biocartis Group NV: Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results

02:00 EST 29 Nov 2018 | GlobalNewsWire (2014)
This article has expired, however you can still download the PDF.
Preview:
PRESS RELEASE: 29 November 2018, 07:00 CET  Biocartis and AstraZeneca Enter Into Agreement  Aimed at Faster Lung Cancer Biomarker Results   Mechelen, Belgium, 29 November 2018 - Biocartis Group NV (the 'Company' or 'B...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Biocartis Group NV: Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results "

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...